

# Thorsten Maretzky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7794900/publications.pdf>

Version: 2024-02-01

42  
papers

3,812  
citations

257450

24  
h-index

265206

42  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4417  
citing authors

#	ARTICLE	IF	CITATIONS
1	CD4 expression in effector T cells depends on DNA demethylation over a developmentally established stimulus-responsive element. <i>Nature Communications</i> , 2022, 13, 1477.	12.8	4
2	Targeting the endo-lysosomal autophagy pathway to treat inflammatory bowel diseases. <i>Journal of Autoimmunity</i> , 2022, 128, 102814.	6.5	11
3	Targeted truncation of the ADAM17 cytoplasmic domain in mice results in protein destabilization and a hypomorphic phenotype. <i>Journal of Biological Chemistry</i> , 2021, 296, 100733.	3.4	9
4	Analysis of the Conditions That Affect the Selective Processing of Endogenous Notch1 by ADAM10 and ADAM17. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1846.	4.1	10
5	Members of the Fibroblast Growth Factor Receptor Superfamily Are Proteolytically Cleaved by Two Differently Activated Metalloproteases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3165.	4.1	8
6	Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy. <i>Pharmaceuticals</i> , 2021, 14, 682.	3.8	8
7	A Disintegrin and Metalloproteases (ADAMs): Activation, Regulation and Mechanisms of Catalysis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8762.	4.1	1
8	The Role of iRhom2 in Metabolic and Cardiovascular-Related Disorders. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 612808.	2.4	8
9	ADAM17 stabilizes its interacting partner inactive RhoBoid 2 (iRhom2) but not inactive RhoBoid 1 (iRhom1). <i>Journal of Biological Chemistry</i> , 2020, 295, 4350-4358.	3.4	12
10	Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains. <i>FASEB Journal</i> , 2020, 34, 4956-4969.	0.5	22
11	Loss of iRhom2 accelerates fat gain and insulin resistance in diet-induced obesity despite reduced adipose tissue inflammation. <i>Metabolism: Clinical and Experimental</i> , 2020, 106, 154194.	3.4	18
12	The Threshold Effect: Lipopolysaccharide-Induced Inflammatory Responses in Primary Macrophages Are Differentially Regulated in an iRhom2-Dependent Manner. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 620392.	3.9	1
13	Novel functions of inactive rhoBoid proteins in immunity and disease. <i>Journal of Leukocyte Biology</i> , 2019, 106, 823-835.	3.3	19
14	Loss of RHBDF2 results in an early-onset spontaneous murine colitis. <i>Journal of Leukocyte Biology</i> , 2019, 105, 767-781.	3.3	26
15	Macrocytic $\beta_2$ -defensins suppress tumor necrosis factor- $\alpha$ (TNF- $\alpha$ ) shedding by inhibition of TNF- $\alpha$ -converting enzyme. <i>Journal of Biological Chemistry</i> , 2018, 293, 2725-2734.	3.4	28
16	The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands. <i>Journal of Cellular Physiology</i> , 2018, 233, 2247-2256.	4.1	16
17	Structural modeling defines transmembrane residues in ADAM17 that are crucial for Rhbdf2/ADAM17-dependent proteolysis. <i>Journal of Cell Science</i> , 2017, 130, 868-878.	2.0	34
18	Characterization of the catalytic properties of the membrane-anchored metalloproteinase ADAM9 in cell-based assays. <i>Biochemical Journal</i> , 2017, 474, 1467-1479.	3.7	16

#	ARTICLE	IF	CITATIONS
19	iRhom2 regulates CSF1R cell surface expression and non-steady state myelopoiesis in mice. <i>European Journal of Immunology</i> , 2016, 46, 2737-2748.	2.9	14
20	Phosphatidylserine exposure is required for ADAM17 sheddase function. <i>Nature Communications</i> , 2016, 7, 11523.	12.8	134
21	The Functional Maturation of A Disintegrin and Metalloproteinase (ADAM) 9, 10, and 17 Requires Processing at a Newly Identified Proprotein Convertase (PC) Cleavage Site. <i>Journal of Biological Chemistry</i> , 2015, 290, 12135-12146.	3.4	59
22	The Cytoplasmic Domain of A Disintegrin and Metalloproteinase 10 (ADAM10) Regulates Its Constitutive Activity but Is Dispensable for Stimulated ADAM10-dependent Shedding. <i>Journal of Biological Chemistry</i> , 2015, 290, 7416-7425.	3.4	34
23	iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6080-6085.	7.1	121
24	Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17. <i>Science Signaling</i> , 2015, 8, ra109.	3.6	60
25	Characterization of Oxygen-Induced Retinopathy in Mice Carrying an Inactivating Point Mutation in the Catalytic Site of ADAM15. <i>Investigative Ophthalmology and Visual Science</i> , 2014, 55, 6774-6782.	3.3	10
26	Phytochemicals Perturb Membranes and Promiscuously Alter Protein Function. <i>ACS Chemical Biology</i> , 2014, 9, 1788-1798.	3.4	241
27	iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 11433-11438.	7.1	138
28	ADAM17 Controls Endochondral Ossification by Regulating Terminal Differentiation of Chondrocytes. <i>Molecular and Cellular Biology</i> , 2013, 33, 3077-3090.	2.3	47
29	iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. <i>Journal of Clinical Investigation</i> , 2013, 123, 928-32.	8.2	129
30	iRhom2 Regulation of TACE Controls TNF-Mediated Protection Against <i>Listeria</i> and Responses to LPS. <i>Science</i> , 2012, 335, 229-232.	12.6	292
31	A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17. <i>Oncogene</i> , 2011, 30, 611-618.	5.9	55
32	Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. <i>Nature Communications</i> , 2011, 2, 229.	12.8	128
33	ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. <i>Journal of Cell Science</i> , 2010, 123, 3913-3922.	2.0	165
34	Src Stimulates Fibroblast Growth Factor Receptor-2 Shedding by an ADAM15 Splice Variant Linked to Breast Cancer. <i>Cancer Research</i> , 2009, 69, 4573-4576.	0.9	30
35	Characterization of the catalytic activity of the membrane-anchored metalloproteinase ADAM15 in cell-based assays. <i>Biochemical Journal</i> , 2009, 420, 105-113.	3.7	48
36	ADAM10-Mediated E-Cadherin Release Is Regulated by Proinflammatory Cytokines and Modulates Keratinocyte Cohesion in Eczematous Dermatitis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1737-1746.	0.7	79

#	ARTICLE	IF	CITATIONS
37	ADAM10 Regulates Endothelial Permeability and T-Cell Transmigration by Proteolysis of Vascular Endothelial Cadherin. <i>Circulation Research</i> , 2008, 102, 1192-1201.	4.5	264
38	ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. <i>Cell Death and Differentiation</i> , 2007, 14, 1040-1049.	11.2	165
39	Regulated ADAM10-dependent Ectodomain Shedding of $\beta$ 3-Protocadherin C3 Modulates Cell-Cell Adhesion. <i>Journal of Biological Chemistry</i> , 2006, 281, 21735-21744.	3.4	94
40	ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and $\beta$ 2-catenin nuclear signalling. <i>EMBO Journal</i> , 2005, 24, 742-752.	7.8	438
41	ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and $\beta$ 2-catenin translocation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9182-9187.	7.1	604
42	L1 Is Sequentially Processed by Two Differently Activated Metalloproteases and Presenilin/ $\beta$ 3-Secretase and Regulates Neural Cell Adhesion, Cell Migration, and Neurite Outgrowth. <i>Molecular and Cellular Biology</i> , 2005, 25, 9040-9053.	2.3	212